BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36760122)

  • 1. Inhibitory machinery for the functional dystroglycan glycosylation.
    Kondo Y; Okajima T
    J Biochem; 2023 Apr; 173(5):333-335. PubMed ID: 36760122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PCYT2 synthesizes CDP-glycerol in mammals and reduced PCYT2 enhances the expression of functionally glycosylated α-dystroglycan.
    Imae R; Manya H; Tsumoto H; Miura Y; Endo T
    J Biochem; 2021 Oct; 170(2):183-194. PubMed ID: 34255834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDP-glycerol inhibits the synthesis of the functional
    Imae R; Manya H; Tsumoto H; Osumi K; Tanaka T; Mizuno M; Kanagawa M; Kobayashi K; Toda T; Endo T
    J Biol Chem; 2018 Aug; 293(31):12186-12198. PubMed ID: 29884773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NAD+ enhances ribitol and ribose rescue of α-dystroglycan functional glycosylation in human FKRP-mutant myotubes.
    Ortiz-Cordero C; Magli A; Dhoke NR; Kuebler T; Selvaraj S; Oliveira NA; Zhou H; Sham YY; Bang AG; Perlingeiro RC
    Elife; 2021 Jan; 10():. PubMed ID: 33513091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ribitol enhances matriglycan of α-dystroglycan in breast cancer cells without affecting cell growth.
    Lu PJ; Tucker JD; Branch EK; Guo F; Blaeser AR; Lu QL
    Sci Rep; 2020 Mar; 10(1):4935. PubMed ID: 32188898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ISPD produces CDP-ribitol used by FKTN and FKRP to transfer ribitol phosphate onto α-dystroglycan.
    Gerin I; Ury B; Breloy I; Bouchet-Seraphin C; Bolsée J; Halbout M; Graff J; Vertommen D; Muccioli GG; Seta N; Cuisset JM; Dabaj I; Quijano-Roy S; Grahn A; Van Schaftingen E; Bommer GT
    Nat Commun; 2016 May; 7():11534. PubMed ID: 27194101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemical and Chemo-Enzymatic Syntheses of Glycans Containing Ribitol Phosphate Scaffolding of Matriglycan.
    Tamura JI; Tamura T; Hoshino S; Imae R; Kato R; Yokono M; Nagase M; Ohno S; Manabe N; Yamaguchi Y; Manya H; Endo T
    ACS Chem Biol; 2022 Jun; 17(6):1513-1523. PubMed ID: 35670527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ISPD Overexpression Enhances Ribitol-Induced Glycosylation of α-Dystroglycan in Dystrophic FKRP Mutant Mice.
    Cataldi MP; Blaeser A; Lu P; Leroy V; Lu QL
    Mol Ther Methods Clin Dev; 2020 Jun; 17():271-280. PubMed ID: 31988979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment of a novel monoclonal antibody against truncated glycoforms of α-dystroglycan lacking matriglycans.
    Yamasaki F; Umezawa F; Sensui T; Anzo M; Abo H; Kuo CW; Khoo KH; Kato K; Yagi H; Kawashima H
    Biochem Biophys Res Commun; 2021 Nov; 579():8-14. PubMed ID: 34583196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ribitol restores functionally glycosylated α-dystroglycan and improves muscle function in dystrophic FKRP-mutant mice.
    Cataldi MP; Lu P; Blaeser A; Lu QL
    Nat Commun; 2018 Aug; 9(1):3448. PubMed ID: 30150693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Muscular Dystrophy with Ribitol-Phosphate Deficiency: A Novel Post-Translational Mechanism in Dystroglycanopathy.
    Kanagawa M; Toda T
    J Neuromuscul Dis; 2017; 4(4):259-267. PubMed ID: 29081423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer Malignancy Is Correlated with Upregulation of PCYT2-Mediated Glycerol Phosphate Modification of α-Dystroglycan.
    Umezawa F; Natsume M; Fukusada S; Nakajima K; Yamasaki F; Kawashima H; Kuo CW; Khoo KH; Shimura T; Yagi H; Kato K
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytidine Diphosphate-Ribitol Analysis for Diagnostics and Treatment Monitoring of Cytidine Diphosphate-l-Ribitol Pyrophosphorylase A Muscular Dystrophy.
    van Tol W; van Scherpenzeel M; Alsady M; Riemersma M; Hermans E; Kragt E; Tasca G; Kamsteeg EJ; Pennings M; van Beusekom E; Vermeulen JR; van Bokhoven H; Voermans NC; Willemsen MA; Ashikov A; Lefeber DJ
    Clin Chem; 2019 Oct; 65(10):1295-1306. PubMed ID: 31375477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystal structures of fukutin-related protein (FKRP), a ribitol-phosphate transferase related to muscular dystrophy.
    Kuwabara N; Imae R; Manya H; Tanaka T; Mizuno M; Tsumoto H; Kanagawa M; Kobayashi K; Toda T; Senda T; Endo T; Kato R
    Nat Commun; 2020 Jan; 11(1):303. PubMed ID: 31949166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endogenous reductase activities for the generation of ribitol-phosphate, a CDP-ribitol precursor, in mammals.
    Hoshino S; Manya H; Imae R; Kobayashi K; Kanagawa M; Endo T
    J Biochem; 2024 Mar; 175(4):418-425. PubMed ID: 38140954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell endogenous activities of fukutin and FKRP coexist with the ribitol xylosyltransferase, TMEM5.
    Nishihara R; Kobayashi K; Imae R; Tsumoto H; Manya H; Mizuno M; Kanagawa M; Endo T; Toda T
    Biochem Biophys Res Commun; 2018 Mar; 497(4):1025-1030. PubMed ID: 29477842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDP-ribitol prodrug treatment ameliorates ISPD-deficient muscular dystrophy mouse model.
    Tokuoka H; Imae R; Nakashima H; Manya H; Masuda C; Hoshino S; Kobayashi K; Lefeber DJ; Matsumoto R; Okada T; Endo T; Kanagawa M; Toda T
    Nat Commun; 2022 Apr; 13(1):1847. PubMed ID: 35422047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous intramuscular transplantation of engineered satellite cells induces exosome-mediated systemic expression of Fukutin-related protein and rescues disease phenotype in a murine model of limb-girdle muscular dystrophy type 2I.
    Frattini P; Villa C; De Santis F; Meregalli M; Belicchi M; Erratico S; Bella P; Raimondi MT; Lu Q; Torrente Y
    Hum Mol Genet; 2017 Oct; 26(19):3682-3698. PubMed ID: 28666318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fukutin-Related Protein: From Pathology to Treatments.
    Ortiz-Cordero C; Azzag K; Perlingeiro RCR
    Trends Cell Biol; 2021 Mar; 31(3):197-210. PubMed ID: 33272829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-terminal domain on dystroglycan enables LARGE1 to extend matriglycan on α-dystroglycan and prevents muscular dystrophy.
    Okuma H; Hord JM; Chandel I; Venzke D; Anderson ME; Walimbe AS; Joseph S; Gastel Z; Hara Y; Saito F; Matsumura K; Campbell KP
    Elife; 2023 Feb; 12():. PubMed ID: 36723429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.